StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI and MBDA Commit to Weapons Collaboration21.7.2026 16:00:00 CEST | Press release
Companies Will Integrate SPEAR Onto MQ-9B and Gambit 6 SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and MBDA have announced a commitment to integrate the European missile-maker's SPEAR precision strike weapons onto new aircraft built by the American uncrewed aircraft manufacturer. GA-ASI President David R. Alexander and MBDA UK Managing Director Chris Allam signed a memorandum of understanding that outlined the agreement at the Farnborough International Airshow 2026. The companies will work together to ensure the MQ-9B remotely piloted aircraft and Gambit 6 collaborative combat aircraft (CCA) can carry and use the SPEAR weapons. "We've built an excellent business relationship with MBDA as part of the integration of the Brimstone missile onto the UK's Protector," said Mr. Alexander. "So, working with MBDA to enable SPEAR on our broader MQ-9B line, and our Gambit CCA, feels like a very natural extension of our partnership." Protect
CHAR Tech Welcomes France's Regulatory Advance Opening Biogas Certificate Support to Pyrolysis21.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 21, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) France proposes opening its flagship renewable gas support scheme (the CPB) to pyrolysis, putting CHAR Tech's HTP technology on the same footing as established production routes in one of Europe's largest gas markets Directly strengthens the HTP project pipeline being developed in France by CHAR Tech's partner GazoTech GazoTech's lead project, Bio-Méthane Provence, is being developed to deploy CHAR Tech's HTP platform to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today welcomed a significant regulatory development in France that, if adopted, would open the country's flagship long-term support mechanism for renewable gas to pyrolysis-based production. The development materially str
Fermi Announces Second Quarter 2026 Earnings Release and Call Date20.7.2026 22:30:00 CEST | Press release
Fermi to host earnings call on August 13, 2026 DALLAS, TX / ACCESS Newswire / July 20, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it plans to release second quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, August 13, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 587288. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B20.7.2026 12:05:00 CEST | Press release
Companies Bring Joint Strike Missile Weapon System to Leading Uncrewed Platform SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and KONGSBERG Gruppen ASA (KONGSBERG) completed the System Requirements Review (SRR) and Preliminary Design Review (PDR) for the integration of the Joint Strike Missile (JSM) weapon system onto MQ-9B. This design and integration effort is a jointly funded project by both companies aimed at providing long-range strike capability for MQ-9B and its customers. These reviews were successfully completed in Kongsberg, Norway, on June 30. MQ-9B is an industry-leading uncrewed aircraft system (UAS) manufactured by GA-ASI and includes the SkyGuardian® and SeaGuardian® models. KONGSBERG produces the JSM, a best-in-class weapon system for use against high-priority targets. "We recognize the value JSM brings to our MQ-9B platform," said Niki Johnson, GA-ASI Vice President, International Capture and Government Affairs. "
GA-ASI Completes Qualification Testing for UK Protector Weapons20.7.2026 12:00:00 CEST | Press release
Concludes 6-Year U.S. and U.K. Governmental and Industry Collaboration SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has completed weapons testing for the Royal Air Force's (RAF) Protector RG Mk1 Remotely Piloted Aircraft, qualifying both the Paveway IV laser-guided bomb and the Brimstone 3 air-to-surface missile for launch from GA-ASI's MQ-9B aircraft. Testing was completed on June 18 at GA-ASI's facilities in Southern California and marked the first time that GA-ASI has taken the lead role in completing weapons qualification for a customer. The qualification testing was conducted under UK Ministry of Defence approval and met all requirements for certification of the safe carriage and release of weapons. "The Royal Air Force is our MQ-9B launch customer and we're here to support them in any way we can," said GA-ASI President David R. Alexander. "Leading the qualification test was a unique experience and we're excited to complete
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom